We hypothesized that tumor surviving Doxil chemotherapy becomes sensitized to cytotoxic lymphocytes and can be effectively targeted by the immune response activated by IL-18, providing the basis for positive therapeutic interactions. Here, IL18 is linked to neoplasm.